Copanlisib+Rituximab Shows Promise for Some Lymphomas

According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone.

The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia, and marginal zone lymphoma.

Copanlisib is a PI3K inhibitor which is currently approved as a stand-alone therapy for relapsed follicular lymphoma. Rituximab is a chimeric monoclonal antibody that targets CD20. It’s used to treat a number of cancers and ailments, including B-cell Non-Hodgkin’s Lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

For more details on the results presented to ASH, see the online article here.

Leave a comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: